A judge has overturned a ruling from the Australian Patent Office that shortened the amount of time available to companies under patent term extensions, saying a “liberal rather than literal” reading was needed to achieve the extension regime’s goals of compensating holders of drug patents for the lengthy time required to obtain regulatory approval to market their drugs.